Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092761 | 1.00 | CTSS (0.49) | CTSSCTSKCXCR3PPARGPPARA | |
| SCHEMBL4510174 | 0.88 | PPARG (0.58) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL4510182 | 0.88 | PPARG (0.58) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL4510911 | 0.87 | PPARA (0.45) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL4510905 | 0.87 | PPARA (0.45) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL4707727 | 0.85 | ACE (0.44) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL4707730 | 0.85 | ACE (0.44) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL5007433 | 0.83 | CTSK (0.57) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL5007432 | 0.83 | CTSK (0.57) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL23878363 | 0.82 | ALDH1A1 (0.47) | CTSSCTSKCXCR3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | CTSS 2921/4885CTSK 3249/4885CXCR3 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.